TBL1XR1 and acute promyelocytic leukemia: Notably, despite existing literature suggesting resistance of TBL1XR1-RARB-positive APL to differentiating agents, our patient demonstrated a favorable clinical response to ATRA and ATO, manifested by gradual defervescence and the development of differentiation syndrome, which was successfully managed with dexamethasone.